Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis

Nature Reviews Rheumatology

Volumn 12, Issue 2, 2016, Pages 78-79

  Dinarello, Charles A ^a,b   Joosten, Leo A B ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; ANTIRHEUMATIC AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; SECUKINUMAB; UNCLASSIFIED DRUG; URIC ACID; ANTIINFLAMMATORY AGENT; BRODALUMAB; CANAKINUMAB; CASPASE INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CANDIDIASIS; CYTOKINE PRODUCTION; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GOUT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ARTHRITIS, GOUTY; EVIDENCE BASED MEDICINE; IMMUNOLOGY; INFLAMMATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOLOGY; TRENDS;

ALPHA 1-ANTITRYPSIN; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, GOUTY; CASPASE INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATOLOGY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84956762498     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.180     Document Type: Review

References (10)

1. Frenzel, E. et al. Acute-phase protein α1-antitrypsin - a novel regulator of angiopoietin-like protein 4 transcription and secretion. J. Immunol. 192, 5354-5362 (2014).
2. Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010).
3. Joosten, L. A. et al. α-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-206966 (2015).
4. Abbate, A. et al. Effects of Prolastin C (plasma-derived α-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-α 1-RT pilot study). Am. J. Cardiol. 115, 8-12 (2015).
5. Crisan, T. O. et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-206564 (2015).
6. Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426-2437 (2009).
7. Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329-1339 (2015).
8. McInnes, I. B. et al. Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 386, 1137-1146 (2015).
9. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
10. Colombel, J. F., Sendid, B., Jouault, T. & Poulain, D. Secukinumab failure in Crohn's disease: the yeast connection? Gut 62, 800-801 (2013).